Please login to the form below

Not currently logged in
Email:
Password:

Abbott wins FDA approval for infant CF dose

Abbott has secured approval for an infant-specific dose of CREON (pancrelipase) to treat exocrine pancreatic insufficiency caused by cystic fibrosis (CF)

Abbott has secured Food and Drug Administration (FDA) approval for an infant-specific dose of CREON (pancrelipase) delayed-release capsules to treat exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis (CF).

The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA, which enable more precise dosing titration in accordance with the Cystic Fibrosis Foundation guidelines.

Most infants with CF require small doses of pancreatic enzyme replacement therapy (PERT) with every feed. Until now, parents or caregivers administering an infant dose of PERT have had to open a capsule of a larger dose and measure out a portion of the contents.

The majority of people living with CF suffer from EPI. They are unable to properly digest food because their bodies do not produce enough pancreatic enzymes, which may lead to malnutrition. The pancreatic enzymes in CREON capsules work directly in the intestines to help break down fats, proteins and carbohydrates, allowing the body to better digest nutrients from food.

Dr Eugene Sun, vice president of global pharmaceutical development at Abbott, said: "We know that the need for consistent, precise dosing of pancreatic enzyme replacement therapy is critical for infants and children living with cystic fibrosis.

"This approval means that CREON will now be available in four dosing options, including both the lowest and highest dosage strengths available to patients in the United States, providing improved dosing titration options and flexibility into adulthood," he added.

15th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics